Cargando…

Bortezomib with standard chemotherapy for children with acute myeloid leukemia does not improve treatment outcomes: a report from the Children’s Oncology Group

New therapeutic strategies are needed for pediatric acute myeloid leukemia (AML) to reduce disease recurrence and treatment-related morbidity. The Children’s Oncology Group Phase III AAML1031 trial tested whether the addition of bortezomib to standard chemotherapy improves survival in pediatric pati...

Descripción completa

Detalles Bibliográficos
Autores principales:	Aplenc, Richard, Meshinchi, Soheil, Sung, Lillian, Alonzo, Todd, Choi, John, Fisher, Brian, Gerbing, Robert, Hirsch, Betsy, Horton, Terzah, Kahwash, Samir, Levine, John, Loken, Michael, Brodersen, Lisa, Pollard, Jessica, Raimondi, Susana, Kolb, Edward Anders, Gamis, Alan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Ferrata Storti Foundation 2020
Materias:	Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7327649/ https://www.ncbi.nlm.nih.gov/pubmed/32029509 http://dx.doi.org/10.3324/haematol.2019.220962

Ejemplares similares

Phenotype in combination with genotype improves outcome prediction in acute myeloid leukemia: a report from Children’s Oncology Group protocol AAML0531
por: Voigt, Andrew P., et al.
Publicado: (2017)

Blood Count Recovery Following Induction Therapy for Acute Myeloid Leukemia in Children Does Not Predict Survival
por: Pommert, Lauren, et al.
Publicado: (2022)

ABCB1 SNP predicts outcome in patients with acute myeloid leukemia treated with Gemtuzumab ozogamicin: a report from Children’s Oncology Group AAML0531 Trial
por: Rafiee, Roya, et al.
Publicado: (2019)

Quality of life in pediatric acute myeloid leukemia: Report from the Children's Oncology Group
por: Nagarajan, Rajaram, et al.
Publicado: (2019)

Ethnic Variation of TET2 SNP rs2454206 and Association with Clinical Outcome in Childhood AML: A Report from the Children’s Oncology Group
por: Kutny, Matthew A., et al.
Publicado: (2015)

Clinical relevance of proteomic profiling in de novo pediatric acute myeloid leukemia: a Children’s Oncology Group study
por: Hoff, Fieke W., et al.
Publicado: (2022)

High expression of myocyte enhancer factor 2C (MEF2C) is associated with adverse-risk features and poor outcome in pediatric acute myeloid leukemia: a report from the Children’s Oncology Group
por: Laszlo, George S., et al.
Publicado: (2015)

Erratum to: High expression of myocyte enhancer factor 2C (MEF2C) is associated with adverse-risk features and poor outcome in pediatric acute myeloid leukemia: a report from the Children’s Oncology Group
por: Laszlo, George S., et al.
Publicado: (2016)

Merging Children’s Oncology Group Data with an External Administrative Database Using Indirect Patient Identifiers: A Report from the Children’s Oncology Group
por: Li, Yimei, et al.
Publicado: (2015)

Early discharge as a mediator of greater ICU‐level care requirements in patients not enrolled on the AAML0531 clinical trial: a Children's Oncology Group report
por: Getz, Kelly D., et al.
Publicado: (2016)

Patient-Reported Outcome Coordinator Did Not Improve Quality of Life Assessment Response Rates: A Report from the Children's Oncology Group
por: Johnston, Donna, et al.
Publicado: (2015)

Comparing Analytic Methods for Longitudinal GWAS and a Case-Study Evaluating Chemotherapy Course Length in Pediatric AML. A Report from the Children's Oncology Group
por: Vujkovic, Marijana, et al.
Publicado: (2016)

MicroRNA Expression-Based Model Indicates Event-Free Survival in Pediatric Acute Myeloid Leukemia
por: Lim, Emilia L., et al.
Publicado: (2017)

Molecular alterations of the IDH1 gene in AML: a Children’s Oncology Group and Southwest Oncology Group study
por: Ho, Phoenix A., et al.
Publicado: (2010)

Population Pharmacokinetic Analysis of Bortezomib in Pediatric Leukemia Patients: Model‐Based Support for Body Surface Area‐Based Dosing Over the 2‐ to 16‐Year Age Range
por: Hanley, Michael J., et al.
Publicado: (2017)

Bortezomib Inpatient Prescribing Practices in Free-Standing Children's Hospitals in the United States
por: DiNofia, Amanda M., et al.
Publicado: (2016)

Aberrantly low STAT3 and STAT5 responses are associated with poor outcome and an inflammatory gene expression signature in pediatric acute myeloid leukemia
por: Narayanan, P., et al.
Publicado: (2021)

Consistent quantitative gene product expression: #1. Automated identification of regenerating bone marrow cell populations using support vector machines
por: Voigt, Andrew P., et al.
Publicado: (2016)

CBFB-MYH11 fusion transcripts distinguish acute myeloid leukemias with distinct molecular landscapes and outcomes
por: Huang, Benjamin J., et al.
Publicado: (2021)

SAMHD1 single nucleotide polymorphisms impact outcome in children with newly diagnosed acute myeloid leukemia
por: Marrero, Richard J., et al.
Publicado: (2023)

Survival Following Relapse in Children with Acute Myeloid Leukemia: A Report from AML-BFM and COG
por: Rasche, Mareike, et al.
Publicado: (2021)

Characteristics and prognostic impact of IDH mutations in AML: a COG, SWOG, and ECOG analysis
por: Zarnegar-Lumley, Sara, et al.
Publicado: (2023)

Consistent quantitative gene product expression: #2. Antigen intensities on bone marrow cells are invariant between individuals
por: Loken, Michael R., et al.
Publicado: (2016)

Integrated stem cell signature and cytomolecular risk determination in pediatric acute myeloid leukemia
por: Huang, Benjamin J., et al.
Publicado: (2022)

Distinct signaling events promote resistance to mitoxantrone and etoposide in pediatric AML: a Children’s Oncology Group report
por: Long, Xin, et al.
Publicado: (2017)

Proteasome subunit expression analysis and chemosensitivity in relapsed paediatric acute leukaemia patients receiving bortezomib-containing chemotherapy
por: Niewerth, Denise, et al.
Publicado: (2016)

Long Noncoding RNA Expression Independently Predicts Outcome in Pediatric Acute Myeloid Leukemia
por: Farrar, Jason E., et al.
Publicado: (2023)

P329: HIGH IMMUNOPROTEASOME ACTIVITY AS NOVEL INDICATOR FOR SENSITIVITY TO BORTEZOMIB-CONTAINING CHEMOTHERAPY IN ACUTE LYMPHOBLASTIC LEUKEMIA PATIENTS FROM CHILDREN’S ONCOLOGY GROUP TRIAL AALL1231
por: Roeten, Margot, et al.
Publicado: (2023)

Comprehensive molecular and clinical characterization of NUP98 fusions in pediatric acute myeloid leukemia
por: Bertrums, Eline J. M., et al.
Publicado: (2023)

Acute Myeloid Leukemia with RAM Immunophenotype: A Pediatric Case with Unusual Morphologic Features
por: Conces, Miriam, et al.
Publicado: (2017)

Genetic mechanisms of primary chemotherapy resistance in pediatric acute myeloid leukemia
por: McNeer, Nicole A., et al.
Publicado: (2019)

Bortezomib in Kidney Transplantation
por: Raghavan, Rajeev, et al.
Publicado: (2010)

Promyelocytic Leukemia with No Retinoic Acid Receptor Alpha Abnormality but with RUNX1T1 Insertion to Chromosome 7q: A Classification and Management Dilemma
por: Overholt, Kathleen, et al.
Publicado: (2015)

DNA Damage Response−Related Proteins Are Prognostic for Outcome in Both Adult and Pediatric Acute Myelogenous Leukemia Patients: Samples from Adults and from Children Enrolled in a Children’s Oncology Group Study
por: Hubner, Stefan E., et al.
Publicado: (2023)

Time to reconsider CD33 single nucleotide polymorphism in the response to gemtuzumab ozogamicin
por: Lamba, Jatinder K., et al.
Publicado: (2021)

Exocytosis of polyubiquitinated proteins in bortezomib-resistant leukemia cells: a role for MARCKS in acquired resistance to proteasome inhibitors
por: Franke, Niels E., et al.
Publicado: (2016)

Bortezomib
por: Rajappa, Senthil
Publicado: (2010)

Progress on the Application of Bortezomib and Bortezomib-Based Nanoformulations
por: Liu, Jianhao, et al.
Publicado: (2021)

Reasons for Non-Completion of Health Related Quality of Life Evaluations in Pediatric Acute Myeloid Leukemia: A Report from the Children’s Oncology Group
por: Johnston, Donna L., et al.
Publicado: (2013)

Aberrant “Barbed-Wire” Nuclear Projections of Neutrophils in Trisomy 18 (Edwards Syndrome)
por: Kahwash, Basil M., et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_avmm8ahqkjesqbs39vftlbabti